Regeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $445.00 by Analysts at Evercore ISI
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price target reduced by Evercore ISI from $605.00 to $445.00 in a research note published on Thursday. They currently have an outperform rating on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the company. UBS AG reiterated a buy rating and issued a $535.00 target price (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 4th. Citigroup Inc. lifted their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a buy rating in a research report on Friday, August 4th. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. Bank of America Corporation reiterated a buy rating and issued a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Credit Suisse Group reiterated a buy rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $475.34.
Regeneron Pharmaceuticals (NASDAQ REGN) traded down $3.10 during mid-day trading on Thursday, reaching $391.59. The company’s stock had a trading volume of 669,073 shares, compared to its average volume of 882,577. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The stock has a market cap of $42,070.00, a P/E ratio of 33.32, a PEG ratio of 1.51 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the business earned $3.13 EPS. equities research analysts anticipate that Regeneron Pharmaceuticals will post 13.55 EPS for the current fiscal year.
In related news, major shareholder Sanofi bought 166,415 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were bought at an average cost of $480.93 per share, with a total value of $80,033,965.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Insiders sold a total of 61,460 shares of company stock worth $29,143,390 in the last three months. Company insiders own 10.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. grew its position in Regeneron Pharmaceuticals by 20.6% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after acquiring an additional 1,199 shares during the last quarter. Dupont Capital Management Corp bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $220,000. Shell Asset Management Co. grew its position in Regeneron Pharmaceuticals by 24.1% during the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after acquiring an additional 2,999 shares during the last quarter. Blair William & Co. IL grew its position in Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after acquiring an additional 79 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 2.4% during the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock worth $56,580,000 after acquiring an additional 2,646 shares during the last quarter. Institutional investors and hedge funds own 67.80% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.